The next edition of the conference will take place on December 13 and 14, 2016.
The venue is even more impressive than last year: Beurs van Berlage, the historic stock exchange building located in the city centre of Amsterdam.
Evaluation and kick-off meeting February 23
A number of people attended the participants meeting February 23 at FHI/MinacNed in Leusden.
The enthusiasm of private companies and institutes to participate in the 2016 edition, underlines the conclusion of the organisation to be right on track in developing an internationally recognized conference in the domain of Micro and Nano Technology.
Register now for participation with a tabletop booth, workshop and/or sponsorship
As of now registration for a table top booth, workshop and sponsorship is open. If you register before April 30 you have priority in choosing your spot on the floor plan of the exhibition. And of course you benefit from maximum exposure in the entire network of the International MicroNanoConference.
The organisers are proud to announce the first keynote speakers for the International MicroNanoConference Amsterdam 2016.
Shane Bowen – Associate Director of Scientific Research at Illumina
Illumina’s goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Illumina is a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality. Their innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
Today, illumina is the global leader in genomics. At the foundation of illumina’s technologies lies an integrated solution that combines traditionally orthogonal scientific and engineering disciplines. Nanofabrication has been instrumental in the realization of the $1000 genome in 2014 and is enabling new solutions to build upon in the future.
Andrew deMello – Professor of Biochemical Engineering ETH Zurich
Andrew deMello is Professor of Biochemical Engineering in the Department of Chemistry and Applied Biosciences at ETH Zurich and Head of the Institute for Chemical and Bioengineering.
His primary specializations include the development of microfluidic devices for high-throughput biological and chemical analysis, ultra-sensitive optical detection techniques, nanofluidic reaction systems for chemical synthesis, novel methods for nanoparticle synthesis, the exploitation of semiconducting materials in diagnostic applications, the development of intelligent microfluidics and the processing of living organisms.
Oliver Paul – professor of Microsystems Engineering (IMTEK), University of Freiburg
Oliver Paul is a professor at the Department of Microsystems Engineering (IMTEK) of the University of Freiburg. He heads the Professorship for MEMS materials and is a co-director of the University of Freiburg’s cluster of excellence BrainLinks-BrainTools.
His research focuses on process technology and materials characterization for MEMS based on silicon technologies, in particular complementary metal oxide silicon (CMOS) technology, as well as silicon based MEMS devices and systems for physical measurements, automation, reliability testing and life science applications.
Peter Seeberger – Professor at the Max-Planck Institute for Colloids and Surfaces
Professor Seeberger is Director at the Max-Planck Institute for Colloids and Surfaces in Potsdam and Professor at the Free University of Berlin. In addition he serves as Affiliate Professor at the Sanford-Burnham Institute for Medical Research (La Jolla, USA) and honorary Professor at the University of Potsdam.
His research focus is on elucidating the role of complex oligosaccharides involved in a host of biological processes of medical relevance by employing molecular tools created by synthetic chemistry. The research in Professor Seeberger’s laboratory has resulted in two spin-off companies: Ancora Pharmaceuticals (Medford, USA) that is currently developing carbohydrate vaccines against malaria and neglected diseases and i2chem (Cambridge, USA) that is commercializing microreactors for chemical applications.